Chevrolet Impala exhibiting major floor rust problems and missing parts looks like the unlucky cousin of all those beautiful ...

Certain animals have evolved remarkable speeds to catch prey or evade predators. The ostrich, impala, and kangaroo showcase nature's incredible ingenuity, leveraging their speed and agility.

Nvidia took the wraps off its latest mid-range gaming GPU at the CES 2025 trade show on January 6 and, despite it having specs that largely align with the RTX 4070, Nvidia claimed this new GPU ...

The Xiaomi 15 features a 6.36-inch CrystalRes AMOLED LTPO display with a 1.5K resolution (2670 × 1200px) and a dynamic refresh rate ranging from 1Hz to 120Hz. The Xiaomi 15 Ultra, on the other ...

Alexa+ is our next-generation AI assistant that seamlessly integrates into your life and helps you get stuff done. It keeps you entertained, helps you stay connected, keeps you organized, and can have ...

EV giant Tesla Inc. TSLA has begun rolling out new driving assistance features for its vehicles on city streets in China, as promised last year. What Happened: The features are being rolled out ...

We get to see the three color options that were expected, and learn about the new features of the camera setup. Xiaomi's upcoming Ultra model will feature a 200 MP telephoto lens. It includes the ...

Xiaomi has once again redefined smartphone imaging with the highly anticipated Xiaomi 15 Ultra, codenamed “Night God.” Following its striking design reveal, the spotlight now turns entirely to ...

LTZ Therapeutics Inc. has gained IND approval from the FDA for LTZ-301, a first-in-class myeloid engager immunotherapy intended to treat relapsed or refractory non-Hodgkin lymphoma (r/r NHL). BioWorld ...

Realme Neo 7x will likely carry a dual rear camera unit Th handset will launch alongside the Realme Neo 7 SE The Realme Neo 7x is expected to support bypass charging ...

REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a phase 1 study set for mid-2025. The FDA cleared the investigational new ...